DGAP-News

WILEX AG: Subsidiary Heidelberg Pharma and Nordic Nanovector Enter into Collaboration to Develop Novel Antibody Drug Conjugates (ADC) - Seite 2

bound to highly potent amatoxin molecules. Amatoxins are small bicyclic
peptides naturally occurring in the death cap mushroom. They inhibit mRNA
transcription by binding to RNA polymerase II, a mechanism that is crucial
for the survival of eukaryotic cells. In preclinical testing, ATACs have
been shown to be highly efficacious, overcoming frequently encountered
resistance mechanisms and combatting even quiescent tumor cells.

Heidelberg Pharma is working on several ATAC candidates with industry
partners as well as on its own ATAC pipeline. The lead candidate HDP-101, a
BCMA ATAC, has been selected for the preclinical and clinical development
in multiple myeloma, the third most common hematologic cancer.

WILEX has diagnostic and therapeutic Phase III drug candidates, which are
available for out-licensing. WILEX is listed at the Frankfurt Stock
Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is
available at www.wilex.com and www.heidelberg-pharma.com.

About Nordic Nanovector

Nordic Nanovector is a biotech company focusing on the development and
commercialization of novel targeted therapeutics in hematology and
oncology. The Company's lead clinical-stage product opportunity is
Betalutin(R), the first in a new class of Antibody-Radionuclide-Conjugates
(ARC) designed to improve upon and complement current options for the
treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with
substantial unmet medical need and orphan drug opportunities, representing
a growing market worth over $12 billion by 2018.

Betalutin(R) comprises a tumor-seeking anti-CD37 antibody, lilotomab
(previously referred to as HH1), conjugated to a low intensity radionuclide
(lutetium-177). The preliminary data has shown promising efficacy and
safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL
patient population. The Company is aiming at developing Betalutin(R) for
the treatment of major types of NHL with first regulatory submission
anticipated in 1H 2019.

Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialization of Betalutin(R) in core markets, while
exploring potential distribution agreements in selected geographies. The
Company is committed to developing its ARC pipeline to treat multiple
selected cancer indications.

Further information about the Company can be found at
www.nordicnanovector.com

This information is subject to the disclose requirements pursuant to
section 5-12 of the Norwegian Securities Trading Act.

Contact                           IR/PR support